Werewolf Therapeutics (HOWL) Stock Forecast, Price Target & Predictions
HOWL Stock Forecast
Werewolf Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 531.58% upside from HOWL’s last price of $1.90) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
HOWL Price Target
The average price target for Werewolf Therapeutics (HOWL) is $12.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 531.58% upside from HOWL's last price of $1.90.
HOWL Analyst Ratings
According to 4 Wall Street analysts, Werewolf Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for HOWL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Werewolf Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Reni Benjamin | JMP Securities | - | - | 98.02% | 531.58% |
The latest Werewolf Therapeutics stock forecast, released on Apr 03, 2024 by Reni Benjamin from JMP Securities, set a price target of $12.00, which represents a 98.02% increase from the stock price at the time of the forecast ($6.06), and a 531.58% increase from HOWL last price ($1.90).
Werewolf Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $1.90 | $1.90 | $1.90 |
| Upside/Downside | -100.00% | -100.00% | 531.58% |
In the current month, the average price target of Werewolf Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Werewolf Therapeutics's last price of $1.90. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 26, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 26, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jun 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 06, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| May 06, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Apr 03, 2024 | JMP Securities | Market Outperform | Outperform | Initialise |
| Apr 03, 2024 | JMP Securities | Market Outperform | Initialise | |
| Aug 24, 2023 | Wedbush | Outperform | Initialise | |
| May 11, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Apr 26, 2022 | Zacks Investment Research | Hold | Upgrade |
Werewolf Therapeutics's last stock rating was published by H.C. Wainwright on Jun 26, 2024. The company gave HOWL a "Underperform" rating, the same as its previous rate.
Werewolf Therapeutics Financial Forecast
Werewolf Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.90M | $8.08M | $4.46M | $7.28M | $4.97M | $4.15M |
| Avg Forecast | - | - | - | - | - | - | - | - | $375.00K | $375.00K | $375.00K | $375.00K | $301.59K | $709.32K | $841.78K | $1.46M | $1.94M | $1.59M | $3.15M | $2.03M | $2.07M | $3.05M | $5.00M |
| High Forecast | - | - | - | - | - | - | - | - | $375.00K | $375.00K | $375.00K | $375.00K | $301.59K | $709.32K | $841.89K | $1.46M | $3.53M | $1.59M | $3.15M | $2.03M | $2.07M | $3.05M | $5.00M |
| Low Forecast | - | - | - | - | - | - | - | - | $375.00K | $375.00K | $375.00K | $375.00K | $301.59K | $709.32K | $841.67K | $1.46M | $353.42K | $1.59M | $3.15M | $2.03M | $2.07M | $3.05M | $5.00M |
| # Analysts | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.71% | 2.57% | 2.20% | 3.51% | 1.63% | 0.83% |
Werewolf Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $1.94M, with a low forecast of $353.42K, and a high forecast of $3.53M. HOWL's average Quarter revenue forecast represents a -67.04% decrease compared to the company's last Quarter revenue of $5.90M (Sep 23).
Werewolf Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-9.25M | $-5.10M | $-12.22M | $-13.18M | $-12.13M | $-14.79M |
| Avg Forecast | - | - | - | - | - | - | - | - | $75.00K | $75.00K | $75.00K | $75.00K | $60.32K | $141.86K | $168.36K | $291.49K | $388.76K | $318.20K | $630.00K | $406.67K | $414.40K | $610.00K | $1000.00K |
| High Forecast | - | - | - | - | - | - | - | - | $75.00K | $75.00K | $75.00K | $75.00K | $60.32K | $141.86K | $168.38K | $291.53K | $706.83K | $318.20K | $630.00K | $406.67K | $414.40K | $610.00K | $1000.00K |
| Low Forecast | - | - | - | - | - | - | - | - | $75.00K | $75.00K | $75.00K | $75.00K | $60.32K | $141.86K | $168.33K | $291.44K | $70.68K | $318.20K | $630.00K | $406.67K | $414.40K | $610.00K | $1000.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.07% | -8.09% | -30.06% | -31.80% | -19.89% | -14.79% |
undefined analysts predict HOWL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Werewolf Therapeutics's previous annual EBITDA (undefined) of $NaN.
Werewolf Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.29M | $-5.10M | $-11.32M | $-10.68M | $-11.35M | $-14.22M |
| Avg Forecast | $-18.16M | $-15.78M | $-13.80M | $-13.91M | $-12.48M | $-11.58M | $-10.74M | $-10.05M | $-21.42M | $-22.84M | $-24.26M | $-23.27M | $-18.14M | $-17.70M | $-16.44M | $-14.95M | $-18.53M | $-16.87M | $-18.44M | $-20.98M | $-23.86M | $-25.57M | $-12.84M |
| High Forecast | $-18.16M | $-15.78M | $-13.80M | $-13.91M | $-12.48M | $-11.58M | $-10.74M | $-10.05M | $-21.42M | $-22.84M | $-24.26M | $-8.68M | $-9.28M | $-17.70M | $-16.44M | $-14.95M | $-12.50M | $-16.87M | $-18.44M | $-20.98M | $-23.86M | $-25.57M | $-12.84M |
| Low Forecast | $-18.16M | $-15.78M | $-13.80M | $-13.91M | $-12.48M | $-11.58M | $-10.74M | $-10.05M | $-21.42M | $-22.84M | $-24.26M | $-46.15M | $-33.74M | $-17.70M | $-16.44M | $-14.95M | $-22.84M | $-16.87M | $-18.44M | $-20.98M | $-23.86M | $-25.57M | $-12.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 0.28% | 0.54% | 0.45% | 0.44% | 1.11% |
Werewolf Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HOWL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Werewolf Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.31M | $4.57M | $4.98M | $4.60M | $4.44M | $5.23M |
| Avg Forecast | - | - | - | - | - | - | - | - | $380.71K | $380.71K | $380.71K | $380.71K | $306.18K | $720.11K | $854.59K | $1.48M | $1.97M | $1.62M | $3.20M | $2.06M | $2.10M | $3.04M | $4.99M |
| High Forecast | - | - | - | - | - | - | - | - | $380.71K | $380.71K | $380.71K | $380.71K | $306.18K | $720.11K | $854.70K | $1.48M | $3.59M | $1.62M | $3.20M | $2.06M | $2.10M | $3.04M | $4.99M |
| Low Forecast | - | - | - | - | - | - | - | - | $380.71K | $380.71K | $380.71K | $380.71K | $306.18K | $720.11K | $854.48K | $1.48M | $358.79K | $1.62M | $3.20M | $2.06M | $2.10M | $3.04M | $4.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.67% | 1.43% | 2.41% | 2.19% | 1.46% | 1.05% |
Werewolf Therapeutics's average Quarter SG&A projection for Dec 23 is $1.97M, based on 3 Wall Street analysts, with a range of $358.79K to $3.59M. The forecast indicates a -54.21% fall compared to HOWL last annual SG&A of $4.31M (Sep 23).
Werewolf Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.23 | $-0.14 | $-0.33 | $-0.35 | $-0.38 | $-0.52 |
| Avg Forecast | $-0.42 | $-0.36 | $-0.32 | $-0.32 | $-0.29 | $-0.26 | $-0.25 | $-0.23 | $-0.49 | $-0.52 | $-0.56 | $-0.53 | $-0.41 | $-0.41 | $-0.38 | $-0.34 | $-0.42 | $-0.39 | $-0.42 | $-0.48 | $-0.55 | $-0.59 | $-0.29 |
| High Forecast | $-0.42 | $-0.36 | $-0.32 | $-0.32 | $-0.29 | $-0.26 | $-0.25 | $-0.23 | $-0.49 | $-0.52 | $-0.56 | $-0.20 | $-0.21 | $-0.41 | $-0.38 | $-0.34 | $-0.29 | $-0.39 | $-0.42 | $-0.48 | $-0.55 | $-0.59 | $-0.29 |
| Low Forecast | $-0.42 | $-0.36 | $-0.32 | $-0.32 | $-0.29 | $-0.26 | $-0.25 | $-0.23 | $-0.49 | $-0.52 | $-0.56 | $-1.06 | $-0.77 | $-0.41 | $-0.38 | $-0.34 | $-0.52 | $-0.39 | $-0.42 | $-0.48 | $-0.55 | $-0.59 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.60% | 0.33% | 0.69% | 0.64% | 0.65% | 1.76% |
According to undefined Wall Street analysts, Werewolf Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HOWL previous annual EPS of $NaN (undefined).
Werewolf Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | - | - | 3511.11% | Buy |
| PASG | Passage Bio | - | - | 1076.47% | Buy |
| VOR | Vor Biopharma | - | - | 659.49% | Buy |
| HOWL | Werewolf Therapeutics | - | - | 531.58% | Buy |
| MOLN | Molecular Partners | - | - | 448.20% | Buy |
| ANEB | Anebulo Pharmaceuticals | - | - | 310.96% | Buy |
| ACRV | Acrivon Therapeutics | - | - | 233.28% | Buy |
| CCCC | C4 Therapeutics | - | - | 217.65% | Buy |
| STOK | Stoke Therapeutics | - | - | 167.72% | Buy |
| ELYM | Eliem Therapeutics | - | - | 154.40% | Buy |
| CGEM | Cullinan Oncology | - | - | 151.20% | Buy |
| CELC | Celcuity | - | - | 138.82% | Buy |
| DSGN | Design Therapeutics | - | - | 72.06% | Buy |
| EWTX | Edgewise Therapeutics | - | - | 39.75% | Buy |
| THRD | Third Harmonic Bio | - | - | 29.51% | Buy |
| IKNA | Ikena Oncology | - | - | -22.22% | Buy |
| CYT | Cyteir Therapeutics | - | - | -33.77% | Sell |